GPC1 and neoplasm: Tumor-bearing mice treated with 50 mg/kg anti-GPC1 mAb had 43-, 17- and 2-fold increase in the mean anti-GPC1 mAb plasma levels as compared with the control, 1 mg/kg and 10 mg/kg anti-GPC1 mAb groups, respectively (P < 0.01 for all; Figure 8B).